Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034916.xml
Nervenheilkunde 2024; 43(07/08): 416-423
DOI: 10.1055/a-2241-9220
DOI: 10.1055/a-2241-9220
Schwerpunkt
Einsatzmöglichkeiten des Botulinum- Neurotoxins bei der Parkinson-Krankheit
ZUSAMMENFASSUNG
Botulinum-Neurotoxin (BoNT) wird seit den 1990er-Jahren in mehreren medizinischen Disziplinen zur Therapie unterschiedlicher Symptome (Spastik, Dystonien, Schmerzen, Sialorrhoe, etc.) eingesetzt und stellt bei etlichen Indikationen die Therapie der Wahl dar. Es hemmt die Freisetzung von Acetylcholin an den motorischen Nerventerminalen und parasympathischen Ganglien, und führt somit zu einer verminderten Aktivierung der behandelten Muskeln bzw. zur Reduktion der autonomen Funktion des behandelten Gewebes. Im Rahmen der Parkinson-Krankheit (PK) wird es zur Therapie motorischer und nicht motorischer Symptome eingesetzt. Für einige Symptome der PK besteht eine Zulassung für die Therapie mit dem BoNT. Für weitere Symptome, die außerhalb der PK vorkommen können, besteht ebenfalls eine Zulassung. Jedoch sind stellenweise die Zulassungen so eng gefasst, dass die spezielle Indikation bei der PK damit nicht der Zulassung entspricht. Im folgenden Text werden die einzelnen Indikationen zur Therapie mit dem BoNT bei der PK vorgestellt.
Publication History
Article published online:
17 July 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Hallett M, Albanese A, Dressler D. et al Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.. Toxicon 2013; 67: 94-114 DOI: 10.1016/j.toxicon.2012.12.004.
- 2 Simpson DM, Hallett M, Ashman EJ. et al Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.. Neurology 2016; 86: 1818-1826 DOI: 10.1212/WNL.0000000000002560.
- 3 Jost WH, Bäumer T, Laskawi R. et al Therapy of sialorrhea with botulinum neurotoxin.. Neurol Ther 2019; 08: 554-563 DOI: 10.1007/s40120-019-00155-6.
- 4 Chinnapongse R, Gullo K, Nemeth P. et al Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson’s disease: a prospective double-blind trial.. Mov Disord 2012; 27: 219-226 DOI: 10.1002/mds.23929.
- 5 Guidubaldi A, Fasano A, Ialongo T. et al Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson’s disease.. Mov Disord 2011; 26: 313-319 DOI: 10.1002/mds.23473.
- 6 Jost WH. Treatment of drooling in Parkinson’s disease with botulinum toxin.. Mov.Disord 1999; 14: 1057 DOI: 10.1002/1531-8257.
- 7 Lagalla G, Millevolte M, Capecci M. et al Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study.. Mov Disord 2006; 21: 704-707 DOI: 10.1002/mds.20793.
- 8 Lagalla G, Millevolte M, Capecci M. et al Long-lasting benefits of botulinum toxin type B in Parkinson’s disease-related drooling.. J Neurol 2009; 256: 563-567 DOI: 10.1007/s00415-009-0085-1.
- 9 Lipp A, Trottenberg T, Schink T. A randomized trial of botulinum toxin A for treatment of drooling.. Neurology 2003; 61: 1279-1281 DOI: 10.1212/wnl.61.9.1279.
- 10 Mancini F, Zangaglia R, Cristina S. et al Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.. Mov Disord 2003; 18: 685-688 DOI: 10.1002/mds.10420.
- 11 Mazlan M, Rajasegaran S, Engkasan JP. et al A double-blind randomized controlled trial investigating the most efficacious dose of botulinum toxin-A for sialorrhea treatment in asian adults with neurological diseases.. Toxins 2015; 07: 3758-3770 DOI: 10.3390/toxins7093758.
- 12 Petracca M, Guidubaldi A, Ricciardi L. et al Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.. Toxicon 2015; 107 Pt A 129-40 DOI: 10.1016/j.toxicon.2015.08.014.
- 13 Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease.. Neurology 2004; 62: 37-40 DOI: 10.1212/01.wnl.0000101713.81253.4c.
- 14 Jost WH, Friedman A, Michel O. et al SIAXI: placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.. Neurology 2019; 92: e1982-e1991 DOI: 10.1212/WNL.0000000000007368.
- 15 Jost WH, Friedman A, Michel O. et al Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.. Parkinsonism Rel Disord 2020; 70: 23-30 DOI: 10.1016/j.parkreldis.2019.11.024.
- 16 Isaacson SH, Ondo W, Jackson CE. et al MYSTICOL Study Group. Safety and efficacy of rimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial.. JAMA Neurol 2020; 77: 461-469 DOI: 10.1001/jamaneurol.2019.4565.
- 17 Lepore V, Duvoisin RC. “Apraxia” of eyelid opening: an involuntary levator inhibition.. Neurology 1985; 35: 423-427 DOI: 10.1212/wnl.35.3.423.
- 18 Martinez-Ramirez D, Giugni JC, Hastings E. et al Comparable botulinum toxin outcomes between primary and secondary blepharospasm: A retrospective analysis.. Tremor Other Hyperkinet Mov 2014; 04: 286 DOI: 10.7916/D8H41Q4X.
- 19 Hellman A, Torres-Russotto D. Botulinum toxin in the management of blepharospasm: current evidence and recent developments.. Ther Adv Neurol Disord 2015; 08 (02) 82-91 DOI: 10.1177/1756285614557475.
- 20 Thiel MF, Altmann CF, Jost WH. Cervical dystonia in Parkinson’s disease: frequency of occurrence and subtypes.. Neurol Neurochir Pol 2022; 56 (04) 379-380 DOI: 10.5603/PJNNS.a2022.0024.
- 21 Tyślerowicz M, Kiedrzyńska W, Adamkiewicz B. et al Cervical dystonia – improving the effectiveness of botulinum toxin therapy.. Neurol Neurochir Pol 2020; 54: 232-242 DOI: 10.5603/PJNNS.a2020.0021..
- 22 Jost WH. Urological problems in Parkinson’s disease: clinical aspects.. J Neural Transm 2013; 120: 587-591 DOI: 10.1007/s00702-012-0914-8.
- 23 Denys P, Le Normand L, Ghout I. et al Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.. Eur Urol 2012; 61 (03) 520-9 DOI: 10.1016/j.eururo.2011.10.028.
- 24 Orasanu B, Mahajan ST. The use of botulinum toxin for the treatment of overactive bladder syndrome.. Indian J Uro 2013; 29 (01) 2-11 DOI: 10.4103/0970-1591.109975.
- 25 Henderson JM, Ghika JA, Van Melle G. et al Botulinum toxin A in non-dystonic tremors.. Eur Neurol 1996; 36: 29-35 DOI: 10.1159/000117196.
- 26 Jankovic J, Schwartz K. Botulinum toxin treatment of tremors.. Neurology 1991; 41: 1185-1188
- 27 Pullman SL, Greene P, Fahn S. et al Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients.. Arch Neurol 1996; 53: 617-624
- 28 Rahimi F, Bee C, Debicki D. et al Effectiveness of BoNT A in Parkinson’s disease upper limb tremor management.. Can J Neurol Sci 2013; 40: 663-669 DOI: 10.1017/s031716710001489x.
- 29 Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors.. Mov Disord 1994; 09: 601-609 DOI: 10.1002/mds.870090604.
- 30 Brin MF, Lyons KE, Doucette J. et al A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.. Neurology 2001; 56 (11) 1523-8 DOI: 10.1212/wnl.56.11.1523.
- 31 Jankovic J, Schwartz K, Clemence W. et al A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor.. Mov Disord 1996; 11 (03) 250-6 DOI: 10.1002/mds.870110306.
- 32 Mittal SO, Machado D, Richardson D. et al Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach.. Mayo Clin Proc 2017; 92 (09) 1359-1367 DOI: 10.1016/j.mayocp.2017.06.010.
- 33 Mittal SO, Machado D, Richardson D. et al Botulinum toxin in essential hand tremor – A randomized double-blind placebo-controlled study with customized injection approach.. Parkinsonism Relat Disord 2018; 56: 65-69 DOI: 10.1016/j.parkreldis.2018.06.019.
- 34 Samotus O, Lee J, Jog M. Personalized Bilateral Upper Limb Essential Tremor Therapy with Botulinum Toxin Using Kinematics.. Toxins 2019; 11 (02) 125 DOI: 10.3390/toxins11020125.
- 35 Samotus O, Lee J, Jog M. Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections.. PLoS One 2017; 12 (06) e0178670
- 36 Samotus O, Lee J, Jog M. Standardized algorithm for muscle selection and dosing of botulinum toxin for Parkinson tremor using kinematic analysis.. Ther Adv Neurol Disord 2020; 13: 1756286420954083 DOI: 10.1177/1756286420954083.
- 37 Colosimo C, Salvatori FM. Injection of the iliopsoas muscle with botulinum toxin in camptocormia.. Mov Disord 2009; 24: 316-317 DOI: 10.1002/mds.22249.
- 38 Fietzek UM, Schroeteler FE, Ceballos-Baumann AO. Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin.. Mov Disord 2009; 24: 2027-2028 DOI: 10.1002/mds.22676.
- 39 Von Coelln R, Raible A, Gasser T. et al Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia.. Mov Disord 2008; 23: 889-892 DOI: 10.1002/mds.21967.
- 40 Lubik S, Jost W, Bönhof J. et al BTX-Injektionen in den M. psoas unter Ultraschallkontrolle.. Der Schmerz 2001; 15: 72
- 41 Etoom M, Alwardat M, Aburub AS. et al Therapeutic interventions for Pisa syndrome in idiopathic Parkinson’s disease. A Scoping Systematic Review.. Clin Neurol Neurosurg 2020; 198: 106242 DOI: 10.1016/j.clineuro.2020.106242.
- 42 Wickremaratchi MM, Knipe MDW, Sastry BSD. et al The motor phenotype of Parkinson’s disease in relation to age at onset.. Mov Disord 2011; 26: 457-463
- 43 Tolosa E, Compta Y. Dystonia in Parkinson’s disease.. J Neurol 2006; 253 (Suppl. 07) DOI: 10.1007/s00415-006-7003-6.
- 44 Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson’s disease.. Lancet Neurol 2005; 04: 423-431 DOI: 10.1016/S1474-4422(05)70119-8.
- 45 Giladi N, Meer J, Honigman S. The use of botulinum toxin to treat “striatal” toes.. J Neurol Neurosurg Psychiatry 1994; 57: 659
- 46 Espay AJ, Vaughan JE, Shukla R. et al Botulinum toxin type A for levodopa-induced cervical dyskinesias in Parkinson’s disease: unfavorable risk-benefit ratio.. Mov Disord 2011; 26 (05) 913-4 DOI: 10.1002/mds.23522.
- 47 Jost WH, Buhmann C. The challenge of pain in the pharmacological management of Parkinson’s disease.. Expert Opin Pharmacother 2019; 20: 1847-1854 DOI: 10.1080/14656566.2019.1639672.
- 48 Schestatsky P, Valls-Solé J, Ehlers JA. et al Hyperhidrosis in Parkinson’s disease.. Mov Disord 2006; 21: 1744-1748 DOI: 10.1002/mds.21006.
- 49 Swinn L, Schrag A, Viswanathan R. et al Sweating dysfunction in Parkinson’s disease.. Mov Disord 2003; 18: 1459-1463 DOI: 10.1002/mds.10586.
- 50 Jost WH. Gastrointestinal dysfunction in Parkinson’s disease.. J Neurol Sci 2010; 289: 69-73
- 51 Alfonsi E, Merlo IM, Ponzio M. et al An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment.. J Neurol Neurosurg Psychiatry 2010; 81: 54-60 DOI: 10.1136/jnnp.2009.174698.
- 52 Alfonsi E, Restivo DA, Cosentino G. et al Botulinum toxin is effective in the management of neurogenic dysphagia. Clinical-electrophysiological findings and tips on safety in different neurological disorders.. Front Pharmacol 2017; 08: 80 DOI: 10.3389/fphar.2017.00080.
- 53 Restivo DA, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson’s disease.. N Engl J Med 2002; 346: 1174-1175 DOI: 10.1056/NEJM200204113461517.
- 54 Mitchell SD, Sidiropoulos C. Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson’s Disease: An Updated Review.. Toxins 2021; 13 (03) 226 DOI: 10.3390/toxins13030226.
- 55 Brisinda G, Sivestrini N, Bianco G. et al Treatment of gastrointestinal sphincters spasms with botulinum toxin A.. Toxins 2015; 07: 1882-1916 DOI: 10.3390/toxins7061882.
- 56 Triadafilopoulos G, Gandhy R, Barlow C. Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson’s disease.. Parkinsonism Relat Disord 2017; 44: 33-37 DOI: 10.1016/j.parkreldis.2017.08.020.
- 57 Albanese A, Maria G, Bentivoglio AR. et al Severe constipation in Parkinson’s disease relieved by botulinum toxin.. Mov Disord 1997; 12: 764-766 DOI: 10.1002/mds.870120524.
- 58 Jost WH, Schrank B, Herold A. et al Functional outlet obstruction: Anismus, spastic pelvic floor syndrome, and dyscoordination of the voluntary sphincter muscles.. Scand J Gastroentero 1999; 34: 449-453 DOI: 10.1080/003655299750026146.
- 59 Giladi N, Gurevich T, Shabtai H. et al The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study.. J Neurol 2001; 248 (07/08) 572-6 DOI: 10.1007/s004150170134.
- 60 Wieler M, Camicioli R, Jones CA. et al Botulinum toxin injections do not improve freezing of gait in Parkinson disease.. Neurology 2005; 65 (04) 626-8 DOI: 10.1212/01.wnl.0000172930.63669.c8.
- 61 Gurevich T, Peretz C, Moore O. et al The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson’s disease: a double blind placebo-controlled pilot study.. Mov Disord 2007; 22 (06) 880-3 DOI: 10.1002/mds.21396.